21 / 31
Neumol Pediatr 2016; 11 (1) Sup: S5-S19
C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl
S19
Consenso chileno SER-SOCHINEP para el manejo del asma severo en el niño
50. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE, Liu
AH, et al. Randomized trial of omalizumab (anti-IgE) for asthma
in inner-city children. N Engl J Med 2011;364:1005-15.
51. Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr,
Calatroni A. Preseasonal treatment with either omalizumab or an
inhaled corticosteroid boost to prevent fall asthma exacerbations.
J Allergy Clin Immunol 2015;136:1476-85.
52. Lai T, Wang S, Xu Z, Zhang C, Zhao Y, Hu Y. Long-term
efficacy and safety of omalizumab in patients with persistent
uncontrolled allergic asthma: a systematic review and meta-
analysis. Sci Rep 2015; 5: 8191.
53. Nopp A, Johansson SG, Adédoyin J, Ankerst J, Palmqvist M,
Oman H. After 6 years with Xolair; a 3-year withdrawal follow-up.
Allergy 2010; 65: 56–60.
54. Walsh GM. Severe eosinophilic asthma and mepolizumab.
Lancet Respir Med 2016; 4: 528-9.
55. Deeks ED. Mepolizumab: A Review in Eosinophilic Asthma.
BioDrugs 2016 Jun 16 (Epub ahead of print).
56. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro
W, Sousa S. Mepolizumab and exacerbations of refractory
eosinophilic asthma. N Engl J Med 2009; 360: 973-84.
57. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene
ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM):
a multicentre, double-blind, placebo-controlled trial. Lancet
2012; 380: 651–59.
58. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM,
Chetta A, et al. Mepolizumab treatment in patients with severe
eosinophilic asthma. N Engl J Med 2014; 371: 1198-207.
59. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene
ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of
mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:
1189-97.
60. Blake K, Raissy H. Mepolizumab: A new class of treatment
for adolescents with severe persistent asthma. Pediatric Allergy,
Immunology, and Pulmonology 2016; 29: 49-52.
61. Busse WW, Dahl R, Jenkins C, Cruz AA. Long-acting
muscarinic antagonists: a potential add-on therapy in the
treatment of asthma? Eur Respir Rev 2016; 25: 54–64.
62. Vogelberg C. Emerging role of long-acting anticholinergics
in children with asthma. Curr Opin Pulm Med 2016, 22:74–9.
63. Rodrigo GJ, Castro-Rodriguez JA. Tiotropium for the
treatment of adolescents with moderate to severe symptomatic
asthma: a systematic review with meta-analysis. Ann Allergy
Asthma Immunol 2015; 115: 211-16.
64. Lyseng-Williamson KA, Keating GM. Tiotropium Respimat Soft
Mist inhaler: a guide to its use in chronic obstructive pulmonary
disease (COPD) in the EU. Drugs and Therapy Perspectives 2015;
31(2): 39-44.
65. Bush A, Pedersen S, Hedlin G, Baraldi E, Barbato A, de
Benedictis F, et al. Pharmacological treatment of severe, therapy-
resistant asthma in children: what can we learn from where? Eur
Respir J 2011; 38: 947–58.
66. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey
MV, Arron JR, et al. Lebrikizumab treatment in adults with
asthma. N Engl J Med 2011;365:1088-98.
67. Maselli DJ, Keyt H, Rogers L. Profile of lebrikizumab and
its potential in the treatment of asthma. Journal of Asthma and
Allergy 2015:8 87–92.
68. Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP,
Wenzel SE, et al. IL-4 receptor polymorphisms predict reduction
in asthma exacerbations during response to an anti-IL-4 receptor
α
antagonist. J Allergy Clin Immunol 2012;130:516-22.
69. Antoniu SA, Cojocaru I. Pitrakinra for asthma. Expert Opin.
Biol. Ther 2010 10(11): 1609-15.
70. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda
F, et al.
NEJM 2013; 368(26): 2455-66.
71. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B,
et al. Dupilumab efficacy and safety in adults with uncontrolled
persistent asthma despite use of medium-to-high-dose inhaled
corticosteroids plus a long-acting β2 agonist: a randomised
double-blind placebo-controlled pivotal phase 2b dose-ranging
trial. Lancet 2016; 388(10039): 31-44.